Population pharmacokinetics of vancomycin in premature malaysian neonates: Identification of predictors for dosing determination

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2626-2632

  Lo, Yoke Lin ^a,c   Van Hasselt, Johan G C ^b,c   Heng, Siow Chin ^a   Lim, Chin Theam ^a   Lee, Toong Chow ^a   Charles, Bruce G ^c  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

AREA UNDER THE CURVE; ARTICLE; BODY SIZE; BODY WEIGHT; COMPARTMENT MODEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MONITORING; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALAYSIA; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEWBORN; POSTMENOPAUSE; PREMATURITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SMALL FOR DATE INFANT; STEADY STATE;

ANTI-BACTERIAL AGENTS; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, SMALL FOR GESTATIONAL AGE; MALAYSIA; MODELS, BIOLOGICAL; MONTE CARLO METHOD; RETROSPECTIVE STUDIES; SEPSIS; STATISTICS, NONPARAMETRIC; VANCOMYCIN;

EID: 77952659134     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01370-09     Document Type: Article

References (39)

1. Albrecht, L., M. Rybak, L. Warbasse, and D. Edwards. 1991. Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. Ann. Pharmacother. 25:713-715.
2. Allegaert, K., B. J. Anderson, J. N. van den Anker, S. Vanhaesebrouck, and F. de Zegher. 2007. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther. Drug Monit. 29:284-291.
3. Anderson, B. J., K. Allegaert, J. N. Van den Anker, V. Cossey, and N. H. Holford. 2007. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br. J. Clin. Pharmacol. 63:75-84.
4. Anderson, B. J., and N. H. Holford. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332.
5. Beal, S. L., L. B. Sheiner, and A. Boeckmann (ed.). 2006. NONMEM user's guide (1989-2006). Icon Development Solutions, Ellicott City, MD.
6. Capparelli, E. V., J. R. Lane, G. L. Romanowski, E. J. McFeely, W. Murray, P. Sousa, C. Kildoo, and J. D. Connor. 2001. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J. Clin. Pharmacol. 41:927-934.
7. Center, K. J., A. C. Reboli, R. Hubler, G. L. Rodgers, and S. S. Long. 2003. Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus warneri. J. Clin. Microbiol. 41:4660-4665.
8. Charles, B. G. P., S. R. B. Townsend, P. A. F. Steer, V. J. R. M. Flenady, P. H. F. Gray, and A. M. Shearman. 2008. Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. Ther. Drug Monit. 30:709-716.
9. Chen, Y., R. L. G. Norris, J. J. Schneider, and P. J. Ravenscroft. 1992. The influence of vancomycin concentration and the pH of plasma on vancomycin protein binding. J. Pharmacol. Toxicol. Methods 28:57-60.
10. Couto, R. C., E. A. A. Carvalho, T. M. G. Pedrosa, E. R. Pedroso, M. C. Neto, and F. M. Biscione. 2007. A 10-year prospective surveillance of nosocomial infections in neonatal intensive care units. Am. J. Infect. Control 35:183-189.
11. de Hoog, M., J. W. Mouton, and J. N. van den Anker. 2004. Vancomycin: pharmacokinetics and administration regimens in neonates. Clin. Pharmacokinet. 43:417-440.
12. de Hoog, M., R. C. Schoemaker, J. W. Mouton, and J. N. van den Anker. 2000. Vancomycin population pharmacokinetics in neonates. Clin. Pharmacol. Ther. 67:360-367.
13. Devlieger, H., G. Martens, A. Bekaert, R. Eeckels, and R. Vlietinck. 1996. Perinatal activities in Flanders, p. 94-116. The Flemish Centre for the Study of Perinatal Epidemiology, Brussels, Belgium.
14. Ette, E. I., and P. J. Williams. 2004. Population pharmacokinetics I: background, concepts, and models. Ann. Pharmacother. 38:1702-1706.
15. Frattarelli, D. A., H. Ergun, M. Lulic-Botica, V. T. Lehr, and J. V. Aranda. 2005. Vancomycin elimination in human infants with intrauterine growth retardation. Pediatr. Infect. Dis. J. 24:979-983.
16. Frymoyer, A., A. L. Hersh, L. Z. Benet, and B. J. Guglielmo. 2009. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr. Infect. Dis. J. 28:398-402.
17. Garrison, M. W., K. Vance-Bryan, T. A. Larson, J. P. Toscano, and J. C. Rotschafer. 1990. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 34:1925-1931.
18. Gemmell, C. G., D. I. Edwards, A. P. Fraise, F. K. Gould, G. L. Ridgway, and R. E. Warren on behalf of the Joint Working Party of the British Society for Antimicrobial Chemotherapy, Hospital Infection Society and Infection Control Nurses Association. 2006. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J. Antimicrob. Chemother. 57:589-608.
19. Guignard, J. P., and A. Drukker. 1999. Why do newborn infants have a high plasma creatinine? Pediatrics 103:e49.
20. Helgason, K. O., A. H. Thomson, and C. Ferguson. 2008. A review of vancomycin therapeutic drug monitoring recommendations in Scotland. J. Antimicrob. Chemother. 61:1398-1399.
21. Hinchliffe, S. A., M. R. J. Lynch, P. H. Sargent, C. V. Howard, and D. Velzen. 1992. The effect of intrauterine growth retardation on the development of renal nephrons. Br. J. Obstet. Gynaecol. 99:296-301.
22. Holford, N. H. G. 1996. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30:329-332.
23. Iwamoto, T., Y. Kagawa, M. Kojima, T. Iwamoto, Y. Kagawa, and M. Kojima. 2003. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol. Pharm. Bull. 26:876-879.
24. Jeffres, M. N., W. Isakow, J. A. Doherty, P. S. McKinnon, D. J. Ritchie, S. T. Micek, and M. H. Kollef. 2006. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 130:947-955.
25. Kimura, T., K. Sunakawa, N. Matsuura, H. Kubo, S. Shimada, and K. Yago. 2004. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob. Agents Chemother. 48:1159-1167.
26. Kobayashi, Y. 2005. Study of the synergism between carbapenems and vancomycin or teicoplanin against MRSA, focusing on S-4661, a carbapenem newly developed in Japan. J. Infect. Chemother. 11:259-261.
27. Lodise, T. P., N. Patel, B. M. Lomaestro, K. A. Rodvold, and G. L. Drusano. 2009. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 49:507-514.
28. Moise-Broder, P. A., A. Forrest, M. C. Birmingham, and J. J. Schentag. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43:925-942.
29. Mongelli, M., and A. Biswas. 2001. A fetal growth standard derived from multiple modalities. Early Hum. Dev. 60:171-177.
30. Pachi, A., R. Lubrano, E. Maggi, A. Giancotti, M. Elli, O. Mannarino, and M. A. Castello. 1993. Renal tubular damage in fetuses with intrauterine growth retardation. Fetal Diagn. Ther. 8:109-113.
31. R Development Core Team. 2008. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
32. Robinson, D., C. P. Weiner, K. T. Nakamura, and J. E. Robillard. 1990. Effect of intrauterine growth retardation on renal function on day one of life. Am. J. Perinatol. 7:343-346.
33. Rodvold, K. A., J. A. Everett, R. D. Pryka, and D. M. Kraus. 1997. Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children. Clin. Pharmacokinet. 33:32-51.
34. Rybak, M., B. Lomaestro, J. C. Rotschafer, R. Moellering, Jr., W. Craig, M. Billeter, J. R. Dalovisio, and D. P. Levine. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm. 66:82-98.
35. Silver, L. E., P. J. Decamps, L. M. Korst, L. D. Platt, and L. C. Castro. 2003. Intrauterine growth restriction is accompanied by decreased renal volume in the human fetus. Am. J. Obstet. Gynecol. 188:1320-1325.
36. Tiskumara, R., S. H. Fakharee, C. Q. Liu, P. Nuntnarumit, K. M. Lui, M. Hammoud, J. K. Lee, C. B. Chow, A. Shenoi, R. Halliday, and D. Isaacs. 2009. Neonatal infections in Asia. Arch. Dis. Child. Fetal Neonatal Ed. 94:F144-F148.
37. Tobin, C. M., J. M. Darville, A. H. Thomson, G. Sweeney, J. F. Wilson, A. P. MacGowan, and L. O. White. 2002. Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. J. Antimicrob. Chemother. 50:713-718.
38. Usher, R., and F. McLean. 1969. Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks. J. Pediatr. 74:901-910.
39. Venables, W. N., and B. D. Ripley. 2002. Modern applied statistics with S, 4th ed. Springer, New York, NY.